Adjunct faculty typically have an academic or research appointment at another institution and contribute or collaborate with one or more School of Medicine faculty members or programs.
Adjunct rank detailsDeborah Doroshow, MD, PhD
Assistant Professor AdjunctAbout
Copy Link
Titles
Assistant Professor Adjunct
Academic Affiliate in the History of Medicine
Biography
Deborah Doroshow is Assistant Professor of Medicine at the Icahn School of Medicine at Mount Sinai and Adjunct Assistant Professor of the History of Medicine at the Yale University School of Medicine.
She graduated from Harvard College in 2004 with a B.A. in History and Science, where she wrote a senior thesis entitled "The Injection of Insulin Into American Psychiatry," which explored the history of insulin coma therapy for schizophrenia. It was awarded the Thomas Temple Hoopes Award for outstanding senior thesis, and a portion of it was subsequently published in the Journal of the History of Medicine and Allied Sciences.
She earned her Ph.D. in History with distinction (concentration in the History of Science and Medicine) from Yale University in December 2012, winning the Edwin W. Small prize for outstanding dissertation in American History and the Pressman Career Development Award from the American Association of the History of Medicine. Her book, Emotionally Disturbed: A History of Caring for America's Troubled Children, was published by the University of Chicago Press in 2019.
Additional historical work has included a study of bedwetting alarms and parenting practices in mid-twentieth century America (Isis, 2010) and a history of laws mandating premarital syphilis testing (Social History of Medicine, 2019). She is an active member of the American Association for the History of Medicine and enjoys mentoring clinician-historians in training.
Deborah earned her M.D. from Harvard Medical School in 2013. She completed her internship and residency in internal medicine at the Yale University School of Medicine in 2015 and her fellowship in hematology and oncology, also at Yale, in 2019. At Mount Sinai, she treats adults with lung cancer as well as adults with a variety of solid tumors as part of the Early Phase Trials Unit, where her work focuses on the DNA damage response.
Appointments
History of Medicine
Assistant Professor AdjunctPrimary
Other Departments & Organizations
Education & Training
- Resident
- Yale University School of Medicine (2015)
- MD
- Harvard Medical School (2013)
- PhD
- Yale University, History (2012)
- AB
- Harvard College, History and Science (2004)
Research
Copy Link
Overview
Medical Research Interests
ORCID
0000-0002-2221-9818
Research at a Glance
Yale Co-Authors
Publications Timeline
Research Interests
Patricia LoRusso, DO
Michael Cecchini, MD
Elizabeth Horn Prsic, MD
Erin Hofstatter, MD
Jeffrey Sklar, MD, PhD
Maryam Lustberg, MD, MPH
History of Medicine
Lung Neoplasms
Publications
2026
Resistance to Immune Checkpoint Inhibitor Treatment in Non-Small Cell Lung Cancer Clinical Trials: A Perspective From Lung-MAP Investigators.
Doroshow D, Leal T, Waqar S, Borghaei H, Camidge D, Dragnev K, Edelman M, Gandara D, Gerber D, Gray J, Hirsch F, Husain H, Kozono D, Leighl N, Li B, Mack P, Neal J, Paik P, Patel S, Riess J, Redman M, Reckamp K. Resistance to Immune Checkpoint Inhibitor Treatment in Non-Small Cell Lung Cancer Clinical Trials: A Perspective From Lung-MAP Investigators. Journal Of Clinical Oncology 2026, jco2501896. PMID: 42234933, DOI: 10.1200/jco-25-01896.Peer-Reviewed Original ResearchAltmetricTargeted therapy for DNA damage response and homologous recombination repair defects: The Olaparib Combinations trial
Doroshow D, Shapiro G, Do K, Keedy V, Mahdi H, Sohal D, Hafez N, LoRusso P, Cecchini M, Sklar J, Mortimer P, Glover C, Moses J, Jürgensmeier J, Eder J. Targeted therapy for DNA damage response and homologous recombination repair defects: The Olaparib Combinations trial. Cancer 2026, 132: e70332. PMID: 41808580, DOI: 10.1002/cncr.70332.Peer-Reviewed Original ResearchCitationsAltmetricMeSH KeywordsEvolving Trends in Latin American Participation in Global Oncology Clinical Trials: A Decade of Phase III Activity (2013-2022)
de la Fuente R, Karol A, Markus A, Argulian A, Omori R, Fujiwara Y, Joshi H, Doroshow D, Galsky M. Evolving Trends in Latin American Participation in Global Oncology Clinical Trials: A Decade of Phase III Activity (2013-2022). JCO Global Oncology 2026, 12: e2500411. PMID: 41719503, DOI: 10.1200/go-25-00411.Peer-Reviewed Original ResearchCitationsAltmetricCOVID-19 in Patients With Gynecologic Cancer: A Report From the COVID-19 and Cancer Consortium
Brown A, Hsu C, Mohsin A, Prescott L, Beeghly A, Ruiz-Garcia E, Vilar-Compte D, García-Gordillo J, Hwang C, Hijaz M, Buekers T, Singh S, Wise-Draper T, Ferrara E, McKay R, Ajmera A, Mariano M, Bhatt P, Nagaraj G, Puc M, Cosin J, Bashir B, Russell K, Halabi S, McManus H, Accordino M, Mavromatis B, Joshi M, Polimera H, Del Prete S, Rose S, Subbiah S, Faller B, Mansoor A, Eid M, Mishra S, O'Cearbhaill R, Crispens M, Shyr Y, Warner J, Halmos B, Verma A, Gartrell B, Ohri N, Sica R, Stockerl-Goldstein K, Butt O, Fiala M, Henderson J, Monahan R, Zhou A, Hallmeyer S, Bohachek P, Mundt D, Pandravada S, Patel M, Streckfuss M, Tadesse E, Thompson M, Revankar S, Peters M, Bindal P, Patel J, Piper-Vallillo A, Warner J, Arvanitis P, Egan P, Farmakiotis D, Khan H, Klein E, Mishra S, Mohsin A, Olszewski A, Vieira K, Del Prete S, Bar M, Gulati A, Lo K, Rose S, Stratton J, Weinstein P, Garcia J, Routy B, Fu P, Shouse G, Hoppenot C, Li A, Choueiri T, Bakouny Z, Connors J, Demetri G, Florez (Duma) N, Freeman D, Giordano A, Labaki C, Morgans A, Nohria A, Saliby R, Schmidt A, Van Allen E, Xu W, Zon R, El Zarif T, Halabi S, Dzimitrowicz H, Zhang T, Lyman G, Graber J, Grivas P, Hawley J, Loggers E, Lynch R, Nakasone E, Schweizer M, Tachiki L, Vinayak S, Wagner M, Yeh A, Gatson N, Dansoa Y, Makary M, Manikowski J, Vadakara J, Yossef K, Goyal S, Huynh-Le M, Rosenstein L, Yu P, Clement J, Daher A, Dailey M, Elias R, Jayaraj A, Hsu E, Menendez A, Serrano O, Hwang C, Gadgeel S, Tejwani S, Accordino M, Bhutani D, Hershman D, Ingham M, Bernicker E, Deeken J, Shafer D, Ruíz-García E, de-la-Rosa-Martinez D, Ramirez A, Vilar-Compte D, Lewis M, Rhodes T, Gill D, Low C, Mashru S, Mansoor A, Hayes-Lattin B, Cohen A, McWeeney S, Nemecek E, Williamson S, Lewis G, Smith S, Nagaraj G, Akhtari M, Castillo D, Reeves M, Berg S, Knox N, O'Connor T, Wehbe F, Altman J, Gurley M, Mulcahy M, Durbin E, Kulkarni A, Nelson H, Sachs Z, Rosovsky R, Reynolds K, Bardia A, Boland G, Fu J, Gainor J, Zubiri L, Halfdanarson T, Bekaii-Saab T, Desai A, Riaz I, Shah S, Smith K, Williams C, Shah D, Bonnen M, Mahadevan D, Ramirez A, Salazar M, Shah P, Bouganim N, Elkrief A, Panasci J, Vinh D, Nanchal R, Singh H, Riely G, Philip J, Faller B, McKay R, Ajmera A, Brouha S, Choi S, Hsiao A, Kligerman S, Nonato T, Reid E, Weissmann L, Bhatt P, Jani C, Mariano M, Thomson C, Blau S, Jhawar S, Addison D, Chen J, Gatti-Mays M, Palmer J, Stover D, Wall S, Williams N, Joshi M, Polimera H, Pomerantz L, Rovito M, Griffiths E, Advani P, Puzanov I, Jabbour S, Misdary C, Shah M, Batist G, Cook E, Dutra M, Ferrario C, Miller W, Bashir B, McNair C, Mahmood S, Mico V, Rivera A, Shah S, Cabebe E, Glover M, Jha A, Khaki A, Schapira L, Tsu-Yu Wu J, Subbiah S, Flora D, Kloecker G, Logan B, Mandapakala C, Russell K, DeCardenas K, Stith B, Edwin N, Smits M, Chism D, Owenby S, Doroshow D, Galsky M, Fazio A, Huber K, Sueyoshi M, Gulati S, Riess J, Patel K, Koshkin V, Borno H, Kwon D, Small E, Zhang S, Rubinstein S, Wood W, Andermann T, Jensen C, Wise-Draper T, Ahmad S, Grover P, Gulati S, Kharofa J, Latif T, Marcum M, Sohal D, Zamulko O, Bowles D, Geiger C, Markham M, Russ A, Saker H, Acoba J, Rho Y, Nguyen R, Feldman L, Gantt G, Hoskins K, Liu L, Khan M, Pasquinelli M, Schwartz C, Venepalli N, Wulff-Burchfield E, Kasi A, Rock C, Friese C, Fecher L, Boldt A, Yoon J, Mavromatis B, Bijjula R, Zaman Q, Reid S, Brown A, Cheng A, Croessmann S, Davis E, Enriquez K, Gillaspie E, Hausrath D, Johnson D, Li X, Slosky D, Solorzano C, Sun T, Tucker M, Wang L, Puc M, Carducci T, Goldsmith K, Van Loon S, Song Q, Topaloglu U, Moore J, Peddi P, Rosen L, McCollough B, Bilen M, Castellano C, Ravindranathan D, Hafez N, Herbst R, LoRusso P, Lustberg M, Masters T, Stratton C. COVID-19 in Patients With Gynecologic Cancer: A Report From the COVID-19 and Cancer Consortium. JCO Oncology Advances 2026, 3 DOI: 10.1200/oa-25-00191.Peer-Reviewed Original ResearchAltmetric
2025
Who Wins? Professional Identity and the American Association for the History of Medicine's Early Career Scholar Awards
Barr J, Doroshow D, Olszewski T, Ehrenberger K. Who Wins? Professional Identity and the American Association for the History of Medicine's Early Career Scholar Awards. Journal Of The History Of Medicine And Allied Sciences 2025, 81: 111-120. PMID: 41251538, DOI: 10.1093/jhmas/jraf018.Peer-Reviewed Original ResearchCitationsReal-World Outcomes and Subsequent Treatment Patterns in Patients with Advanced Non-Small Cell Lung Cancer and Atypical EGFR Mutations Receiving First-Line Osimertinib Monotherapy
Nieva J, Wang X, Doroshow D, Servidio L, Cooper M, Lau Y, Karia P, Robichaux J. Real-World Outcomes and Subsequent Treatment Patterns in Patients with Advanced Non-Small Cell Lung Cancer and Atypical EGFR Mutations Receiving First-Line Osimertinib Monotherapy. Oncology And Therapy 2025, 14: 225-240. PMID: 41206837, PMCID: PMC12992757, DOI: 10.1007/s40487-025-00395-7.Peer-Reviewed Original ResearchAltmetricDocumentation of patient withdrawals, retention strategies, and postwithdrawal data practices in cancer clinical trials
Karol A, Paredes R, Argulian A, Joshi H, Weintraub L, Oguntuyo K, Miller J, Fujiwara Y, Doroshow D, Galsky M. Documentation of patient withdrawals, retention strategies, and postwithdrawal data practices in cancer clinical trials. Cancer 2025, 131: e70106. PMID: 41004397, DOI: 10.1002/cncr.70106.Peer-Reviewed Original ResearchAltmetricAzenosertib Is a Potent and Selective WEE1 Kinase Inhibitor with Broad Antitumor Activity Across a Range of Solid Tumors
Ma J, Liu W, Li J, Kim D, Kim S, Levy A, Cai Z, Bunker K, Recio-Boiles A, Segar J, Sen S, Doroshow D, Jandial D, Rutgard M, Harismendy O, Grant S, Samatar A, Fischer K, Lackner M. Azenosertib Is a Potent and Selective WEE1 Kinase Inhibitor with Broad Antitumor Activity Across a Range of Solid Tumors. Molecular Cancer Therapeutics 2025, 24: 1171-1185. PMID: 40231599, PMCID: PMC12314526, DOI: 10.1158/1535-7163.mct-24-1194.Peer-Reviewed Original ResearchCitationsAltmetricPGV001, a Multi-Peptide Personalized Neoantigen Vaccine Platform: Phase I Study in Patients with Solid and Hematologic Malignancies in the Adjuvant Setting.
Saxena M, Marron T, Kodysh J, Finnigan J, Onkar S, Kaminska A, Tuballes K, Guo R, Sabado R, Meseck M, O'Donnell T, Sebra R, Parekh S, Galsky M, Blasquez A, Gimenez G, Bicak M, Cimen Bozkus C, Delbeau-Zagelbaum D, Rodriguez D, Acuna-Villaorduna A, Misiukiewicz K, Posner M, Miles B, Irie H, Tiersten A, Doroshow D, Wolf A, Mandeli J, Brody R, Salazar A, Gnjatic S, Hammerbacher J, Schadt E, Friedlander P, Rubinsteyn A, Bhardwaj N. PGV001, a Multi-Peptide Personalized Neoantigen Vaccine Platform: Phase I Study in Patients with Solid and Hematologic Malignancies in the Adjuvant Setting. Cancer Discovery 2025, 15: 930-947. PMID: 40094414, DOI: 10.1158/2159-8290.cd-24-0934.Peer-Reviewed Original ResearchCitationsAltmetricInpatient Immunotherapy Outcomes Study: A Multicenter Retrospective Analysis
Riaz F, Zhu H, Dickerson J, Sayegh H, Brongiel S, Baldwin E, Kier M, Zaemes J, Hearn C, Abdelghany O, Cohen R, Parikh R, Reuss J, Prsic E, Doroshow D. Inpatient Immunotherapy Outcomes Study: A Multicenter Retrospective Analysis. JCO Oncology Practice 2025, 21: 1165-1173. PMID: 39937997, DOI: 10.1200/op-24-00788.Peer-Reviewed Original ResearchCitationsAltmetric
Get In Touch
Copy Link